# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-24-018175
Filing Date
2024-04-25
Accepted
2024-04-25 16:16:00
Documents
20
Period of Report
2024-06-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | bcrx-20240425.htm iXBRL | DEF 14A | 1222234
6 | GRAPHIC | bcrx-20240425_g1.jpg | GRAPHIC | 22227
7 | GRAPHIC | bcrx-20240425_g2.jpg | GRAPHIC | 127983
8 | GRAPHIC | bcrx-20240425_g3.jpg | GRAPHIC | 109513
9 | GRAPHIC | bcrx-20240425_g4.jpg | GRAPHIC | 118233
10 | GRAPHIC | bcrx-20240425_g5.jpg | GRAPHIC | 129533
11 | GRAPHIC | bcrx-20240425_g6.jpg | GRAPHIC | 96447
| Complete submission text file | 0001628280-24-018175.txt |  | 3346831

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
2 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | bcrx-20240425.xsd | EX-101.SCH | 2355
3 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | bcrx-20240425_def.xml | EX-101.DEF | 2391
4 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | bcrx-20240425_lab.xml | EX-101.LAB | 2738
5 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | bcrx-20240425_pre.xml | EX-101.PRE | 1472
23 | EXTRACTED XBRL INSTANCE DOCUMENT | bcrx-20240425_htm.xml | XML | 99104

Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-23186 | Film No.: 24876528
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)